Cantor initiates coverage on Aquestive Therapeutics, highlighting Anaphylm's potential to disrupt the epinephrine auto-injector market with 200% upside.
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Aquestive Therapeutics hosted a virtual investor day, announcing advancements in Anaphylm and AQST-108. The company aims for FDA meetings in late 2024, targeting a 2025 NDA submission, while HC Wainwright raises its price target amid promising developments.
AQST stock results show that Aquestive Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Shares of STAAR Surgical Company (NASDAQ: STAA) rose sharply during Thursday’s session after the company issued strong preliminary first-quarter net sales guidance. STAAR Surgical shares jumped 13.3% to $44.30 on Thursday.
U.S. stocks traded higher toward the end of trading, after the Federal Reserve left rates unchanged. The Dow traded up 0.91% to 39,467.76 while the NASDAQ rose 1.08% to 16,341.42. The S&P 500 also rose, gaining, 0.78% to 5,218.70.
Shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) fell sharply during Wednesday’s session after the company announced it concluded its strategic evaluation process, announced management succession and board changes. Lifecore Biomedical shares dipped 31.7% to $4.91 on Wednesday.
U.S. stocks traded mostly flat midway through trading, ahead of interest-rate decision from the Federal Reserve. The Dow traded up 0.03% to 39,123.89 while the NASDAQ fell 0.01% to 16,165.15. The S&P 500 also rose, gaining, 0.01% to 5,178.79.
Shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA) rose sharply in today’s pre-market trading after the company reported a year-over-year increase in FY23 EPS results.
